The WHO's endorsement of lenacapavir, a twice-yearly injectable drug, could transform HIV prevention for high-risk groups, especially amid funding concerns. This breakthrough may help millions and push us closer to an AIDS-free world.
Recent U.S. funding cuts to AIDS programs have sparked alarms, with UNAIDS warning of potential catastrophic rises in HIV infections and AIDS-related deaths. The future of global health hangs in the balance.
A new Covid variant, NB.1.8.1, raises alarms for its potential to spread rapidly and evade antibodies. Meanwhile, the FDA approves a long-lasting HIV injection, and concerns about public safety arise with ICE's rule changes.
In a crucial turn of events, the Trump administration has lifted its freeze on nearly $20 million for HIV prevention programs following significant public outcry. This funding is vital for combating new infections and supporting the LGBTQ+ community.
In a landmark ruling, the U.S. Supreme Court ensures that health insurers must continue to cover preventive services like cancer screenings and HIV medications at no cost to patients. This decision safeguards vital health benefits amidst ongoing challenges to Obamacare.
In a landmark decision, the Supreme Court confirmed the constitutionality of the US Preventive Services Task Force, protecting no-cost health care services for 150 million Americans. This ruling comes as a relief to public health advocates amid challenges from Christian-owned businesses.
Explore groundbreaking health trends from exosome treatments and HIV prevention injections to new obesity pills and brain implants. What do experts really think? Dive into the latest in health innovation and skepticism.
The FDA has approved lenacapavir, a groundbreaking antiviral drug for HIV prevention developed by biochemist Wesley Sundquist. Learn how this drug could change the future of HIV treatment and prevention.
A groundbreaking HIV prevention shot, Yeztugo, has been approved by the FDA, offering hope for at-risk individuals with its twice-yearly injections. However, concerns about cost and accessibility remain.
The FDA has approved Gilead's Yeztugo, a twice-yearly injection that could revolutionize HIV prevention, boasting a 99.9% effectiveness. While hailed as a breakthrough, concerns over pricing remain, with activists urging for affordability.
